Supercharged immune cells take on viruses in transplant patients

NCT ID NCT01325636

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether giving patients special immune cells (T cells) that target CMV or adenovirus could control these infections after a stem cell transplant. Sixteen children and adults received one or two doses of these cells. The goal was to reduce virus levels in the blood safely. The trial was early-stage, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

specific immune cells (CD4 and CD8 T cells) targeting CMV or adenovirus

What this could lead to

If it works, this could offer a way to control dangerous viral infections after stem cell transplants without relying on drugs that have side effects.

What could go wrong

This was a small, early-phase trial with only 16 patients, so results may not apply broadly. The treatment could also cause graft-versus-host disease or other immune reactions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Biotherapy department, Hôpital Necker - Enfants Malades

    Paris, 75743, France